Ultrafiltration comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Testing hydrolysate powders typically begins with proximate analysis for moisture, ash, fat, and total nitrogen. Protein content is calculated from nitrogen using a conversion factor, most often Kjeldahl or Dumas combustion. Peptide size distribution is assessed by size-exclusion chromatography, reversed-phase HPLC, or mass spectrometry. Sodium dodecyl sulfate polyacrylamide gel electrophoresis can show residual intact protein bands. Free amino groups may be quantified by colorimetric assays to estimate cleavage extent, though different methods and laboratories are not always directly comparable.
Dry hydrolysate powders are generally stable when kept cool, dry, and sealed, while moisture uptake can cause caking, Maillard browning, and loss of solubility. Higher temperatures accelerate these changes and may alter flavor. Recommended storage conditions often fall between 15 and 25 degrees Celsius with relative humidity below 60 percent. Once reconstituted, liquid hydrolysate solutions support microbial growth and may develop bitterness or haze over time. Packaging in moisture-barrier containers with desiccants helps maintain quality during transport and warehouse storage.
Quality control for hydrolysate ingredients focuses on identity, purity, and consistency, with specifications that may include total protein, hydrolysis level, molecular weight distribution, microbiological limits, heavy metals, and allergen labeling. In some jurisdictions, partially and extensively hydrolyzed formulas are regulated as foods for special dietary uses or as infant formula ingredients. Regulatory status varies by country and intended use. Documentation such as certificates of analysis, safety data sheets, and method validation records supports traceability. Open questions remain about standardizing hydrolysis measurements across suppliers and laboratories.
Whey protein hydrolysate is a dairy ingredient made by treating whey protein with proteolytic enzymes. The starting material is whey, the liquid remaining after cheese or casein production, and its main proteins include beta-lactoglobulin, alpha-lactalbumin, and bovine serum albumin. Enzyme action breaks peptide bonds, producing shorter peptides and some free amino acids. The result is not a single uniform substance; composition depends on whey source, enzyme type, hydrolysis conditions, and downstream filtration. Hydrolysates are often described by average peptide length or degree of hydrolysis rather than by one fixed molecular weight.
Compared with whey protein concentrate or isolate, hydrolysate has a smaller average peptide size and a higher proportion of low-molecular-weight fractions. This change can affect solubility, viscosity, osmolality, taste, and foam formation. Some hydrolysates are bitter because hydrophobic peptides are exposed during cleavage. The term hydrolysate does not indicate a guaranteed peptide profile; two products with the same reported hydrolysis value can differ in peptide sequence and residual intact protein. Commercial specifications usually state protein content, moisture, ash, fat, and microbiology, while peptide distribution may be reported as a range.
Whey protein hydrolysate appears in infant formula, sports nutrition, and clinical nutrition. In infant formula, extensively hydrolyzed products are used when a reduced allergenicity is desired, though not all hydrolysates are hypoallergenic. In sports products, the ingredient is marketed for rapid amino acid delivery, but the practical advantage over intact whey protein remains debated. Research often compares hydrolysate with isolate or concentrate for absorption kinetics, muscle protein synthesis, and gastrointestinal tolerance. Regulatory categories differ by country, and label terms such as partially hydrolyzed or extensively hydrolyzed are defined in some jurisdictions but not others.
| Property | Value | Notes |
|---|---|---|
| Moisture content | ≤5% typical | Higher moisture promotes caking and browning |
| pH (5% solution) | 6.0–7.5 typical | Varies with hydrolysis and neutralization |
| Ash content | 1–8% | Depends on demineralization and neutralization salts |
| Microbiological limit | Total aerobic count <10^4 CFU/g typical | Specifications vary by grade and market |
| Shelf life | 12–24 months unopened | Cool, dry storage extends stability |
Quality control focuses on degree of hydrolysis, molecular weight distribution, protein content, moisture, ash, and microbial limits. Degree of hydrolysis is commonly calculated from the number of cleaved peptide bonds relative to total peptide bonds. Size-exclusion chromatography and mass spectrometry can describe peptide size ranges, while amino acid analysis quantifies composition. Standard methods from dairy science organizations are often used, though no single method captures every functional property. Results are therefore reported alongside processing conditions.
Hydrolysates are generally stable as dry powders but can absorb moisture and undergo browning during warm storage. The bitter taste of some hydrolysates arises from hydrophobic peptides exposed by cleavage, and it varies with enzyme choice and degree of hydrolysis. Reduced allergenicity is sometimes claimed, but residual IgE-binding peptides may remain, especially in partial hydrolysates. Regulatory frameworks treat extensively hydrolyzed and partially hydrolyzed products differently, and labeling rules vary by country. More research is needed on how specific peptide profiles relate to clinical outcomes.
Whey protein hydrolysate is a dairy ingredient produced by treating whey protein concentrate or isolate with proteolytic enzymes, acids, or heat under controlled conditions. The process cleaves peptide bonds and reduces average peptide size compared with intact whey proteins. Products are often described by degree of hydrolysis, which estimates the percentage of peptide bonds broken. Hydrolysates occupy a distinct category from concentrates and isolates because their peptide profile, solubility, and taste differ, even when the parent protein source is similar. Commercial production typically begins with pasteurized whey, followed by filtration, enzymatic treatment, inactivation, and drying.
Enzyme choice, pH, temperature, time, and substrate concentration influence the resulting peptide distribution. Endopeptidases cut internal peptide bonds, while exopeptidases remove terminal amino acids and can reduce bitterness. Manufacturers may combine enzymes or use membrane filtration to select peptide size ranges. A higher degree of hydrolysis generally means more small peptides and free amino acids, but it does not by itself define biological activity or nutritional quality. Batch-to-batch variation arises from raw whey composition, enzyme specificity, and processing parameters, so specification ranges are common in commercial supply.
Dried hydrolysate powders are usually off-white to pale yellow and are marketed as free-flowing powders or liquid concentrates. They are used in foods, beverages, and specialized nutrition products where rapid dispersion or reduced allergenicity is desired, although residual allergenic epitopes can remain depending on hydrolysis extent. The term hydrolysate does not imply a single molecular weight cutoff or a guaranteed clinical effect. Labels may state degree of hydrolysis, protein content, or peptide length profile, but analytical definitions vary across suppliers and jurisdictions.
The lift force is not generated by the air taking the same time to travel above and below an aircraft's wing. This misconception, sometimes called the equal transit-time fallacy, is widespread among textbooks and non-technical reference books, and even appears in pilot training materials. In fact, the air moving over the top of an aerofoil generating lift is always moving much faster than the equal transit theory would imply, as described in the incorrect and correct explanations of lift force.
At times, the mucous membrane around the uvula may swell, causing the uvula to expand 3–5 times its normal size. This condition is known as uvulitis. When the uvula touches the throat or tongue, it can cause sensations like gagging or choking, although there is no foreign matter present. This can cause problems with breathing, talking, and eating. There are many theories about what causes the uvula to swell, including dehydration (e.g. from arid weather); excessive smoking or other inhaled irritants; snoring; allergic reaction; or a viral or bacterial infection. An aphthous ulcer which has formed on the uvula can also cause swelling and discomfort. If the swelling is caused by dehydration, drinking fluids may improve the condition. If the cause is a bacterial infection, gargling salt water may help. However, it can also be a sign of other problems. Some people with a history of recurring uvulitis carry an epinephrine autoinjector to counteract symptoms of an attack. A swollen uvula is not normally life-threatening and subsides in a short time, typically within a day.
== Pharmaceutical use == As a synthetic drug, synephrine first appeared in Europe in the late 1920s, under the name of Sympatol. One of the earliest papers describing its pharmacological and toxicological properties was written by Lasch, who obtained it from the Viennese company Syngala. By 1930, Sympatol was referred to as a Boehringer product, while one of the first US Patents describing its preparation and use was assigned to Frederick Stearns & Co. in 1933. Despite the date of this patent, clinical and pharmacological research on synephrine obtained from Frederick Stearns & Co was being carried out in the US by 1930. Writing in 1931, Hartung reported that in 1930 the Council on Pharmacy and Chemistry of the American Medical Association had accepted synephrine for inclusion in its list of "New and Non-Official Remedies" as an agent for the treatment, by either oral or parenteral administration, "of attacks of hay fever, asthma, coughing, spasms of asthma and pertussis (whooping cough)." However, synephrine was dropped from the council's list in 1934, and its apparent re-advertising as a new drug by the Stearns company ten years later elicited a scathing comment from the Editors of the Journal of the American Medical Association. The third edition (1965) of Drill's Pharmacology in Medicine stated, with reservations, that synephrine was "advertised as an antihistaminic to be used in the treatment of the common cold...", under the trade name of "Synephrin Tartrate", and indicated that the dose was 100 mg, given intramuscularly, or subcutaneously.
Sources: en.wikipedia.org
A fully oxygenated orthorhombic YBa2Cu3O7−x sample can be transformed into tetragonal YBa2Cu3O6 by heating in a vacuum at temperature above 973 K (700 °C). The preparation of Bi-, Tl- and Hg-based high-Tc superconductors is more difficult than the YBCO preparation. Problems in these superconductors arise because of the existence of three or more phases having a similar layered structure. Thus, syntactic intergrowth and defects such as stacking faults occur during synthesis and it becomes difficult to isolate a single superconducting phase. For Bi–Sr–Ca–Cu–O, it is relatively simple to prepare the Bi-2212 (Tc ≈ 85 K) phase, whereas it is very difficult to prepare a single phase of Bi-2223 (Tc ≈ 110 K). The Bi-2212 phase appears only after few hours of sintering at 1,130–1,140 K (860–870 °C), but the larger fraction of the Bi-2223 phase is formed after a long reaction time of more than a week at 1,140 K (870 °C). Although the substitution of Pb in the Bi–Sr–Ca–Cu–O compound has been found to promote the growth of the high-Tc phase, a long sintering time is still required.
== Causes == Elevated blood ketone levels are most often caused by accelerated ketone production but may also be caused by consumption of exogenous ketones or precursors. When glycogen and blood glucose reserves are low, a metabolic shift occurs in order to save glucose for the brain which is unable to use fatty acids for energy. This shift involves increasing fatty acid oxidation and production of ketones in the liver as an alternate energy source for the brain as well as the skeletal muscles, heart, and kidney. Low levels of ketones are always present in the blood and increase under circumstances of low glucose availability. For example, after an overnight fast, 2–6% of energy comes from ketones and this increases to 30–40% after a 3-day fast. The amount of carbohydrate restriction required to induce a state of ketosis is variable and depends on activity level, insulin sensitivity, genetics, age and other factors, but ketosis will usually occur when consuming less than 50 grams of carbohydrates per day for at least three days. Neonates, pregnant women and lactating women are populations that develop physiological ketosis especially rapidly in response to energetic challenges such as fasting or illness. This can progress to ketoacidosis in the setting of illness, although it occurs rarely. Propensity for ketone production in neonates is caused by their high-fat breast milk diet, disproportionately large central nervous system and limited liver glycogen.
Stem-loop Stem-loop intramolecular base pairing is a pattern that can occur in single-stranded DNA or, more commonly, in RNA. The structure is also known as a hairpin or hairpin loop. It occurs when two regions of the same strand, usually complementary in nucleotide sequence when read in opposite directions, base-pair to form a double helix that ends in an unpaired loop. The resulting structure is a key building block of many RNA secondary structures. Cruciform DNA Cruciform DNA is a form of non-B DNA that requires at least a 6 nucleotide sequence of inverted repeats to form a structure consisting of a stem, branch point and loop in the shape of a cruciform, stabilized by negative DNA supercoiling. Two classes of cruciform DNA have been described; folded and unfolded. G-quadruplex G-quadruplex secondary structures (G4) are formed in nucleic acids by sequences that are rich in guanine. They are helical in shape and contain guanine tetrads that can form from one, two or four strands. D-loop A displacement loop or D-loop is a DNA structure where the two strands of a double-stranded DNA molecule are separated for a stretch and held apart by a third strand of DNA. An R-loop is similar to a D-loop, but in this case the third strand is RNA rather than DNA. The third strand has a base sequence which is complementary to one of the main strands and pairs with it, thus displacing the other complementary main strand in the region. Within that region the structure is thus a form of triple-stranded DNA.
=== Computational chemistry and MacroModel === In addition to his contributions to synthetic organic chemistry, Clark Still was an early pioneer in applying computational methods to the study of organic compounds. Conformational analysis was integral to Still's study of macrocyclic stereocontrol, and there was a general need for a fast and reliable computational method for predicting an organic molecule's lowest energy conformation. In order to address the problem, Still and coworkers reported a simple Monte Carlo method for searching conformational space in 1989. In this procedure, the internal coordinates for an organic molecule were varied at random, and the energy of the lowest energy conformation was determined after structure minimization. After each iteration, the minimum energy was compared to the values obtained previously in order to locate the global minimum; Still referred to this overall process as a Monte Carlo multiple-minimum search. In an effort to make molecular modeling more accessible to practicing organic chemists, Still developed the integrated software program MacroModel in 1986 in association with Columbia University. Dr. Wayne Guida, a senior postdoctoral researcher in Still's group at the time, described the development of this software package in the following way:
Sources: en.wikipedia.org
== External links == American Association for Clinical Chemistry American Society for Clinical Pathology American Board of Pathology College of American Pathologists European Federation of Clinical Chemistry and Laboratory Medicine Academy of Clinical Laboratory Physicians and Scientists
=== Processing === The final peptide is often modified, e.g., by glycosylation, acylation, halogenation, or hydroxylation. The responsible enzymes are usually associated to the synthetase complex and their genes are organized in the same operons or gene clusters.
=== Related drugs === Although described as SNRIs, duloxetine (Cymbalta), venlafaxine (Effexor), and desvenlafaxine (Pristiq) are in fact relatively selective as serotonin reuptake inhibitors (SRIs). They are about at least 10-fold selective for inhibition of serotonin reuptake over norepinephrine reuptake. The selectivity ratios are approximately 1:30 for venlafaxine, 1:10 for duloxetine, and 1:14 for desvenlafaxine. At low doses, these SNRIs act mostly as SSRIs; only at higher doses do they also prominently inhibit norepinephrine reuptake. Milnacipran (Ixel, Savella) and its stereoisomer levomilnacipran (Fetzima) are the only widely marketed SNRIs that inhibit serotonin and norepinephrine to similar degrees, both with ratios close to 1:1. Vilazodone (Viibryd) and vortioxetine (Trintellix) are SRIs that also act as modulators of serotonin receptors and are described as serotonin modulators and stimulators (SMS). Vilazodone is a 5-HT1A receptor partial agonist while vortioxetine is a 5-HT1A receptor agonist and 5-HT3 and 5-HT7 receptor antagonist. Litoxetine (SL 81–0385) and lubazodone (YM-992, YM-35995) are similar drugs that were never marketed. They are SRIs and litoxetine is also a 5-HT3 receptor antagonist while lubazodone is also a 5-HT2A receptor antagonist.
Sources: en.wikipedia.org
Keep the powder sealed in a cool, dry place away from direct sunlight and strong odors. Typical targets are 15 to 25 degrees Celsius and low relative humidity. After opening, use within the manufacturer's recommended period.
Size-exclusion chromatography and mass spectrometry provide molecular weight or mass information. Electrophoresis can reveal intact protein bands and larger fragments. No single method captures the complete peptide profile.
Not always, because assays and calculation methods differ. Values may reflect free amino groups, pH change, or nitrogen solubility. Comparisons require method details and reference standards.
It is made from whey, the liquid byproduct of cheese or casein manufacture. The whey protein is treated with enzymes that cleave peptide bonds. The resulting mixture contains peptides of varying lengths plus some free amino acids.